Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Savara brings in initial $3.2mm in Series B round; adds $7.4mm

Executive Summary

Pulmonary drug delivery firm Savara Pharmaceuticals has raised $3.2mm so far through its Series B venture round. (An extension to the financing is expected in the near future.) The Keiretsu Forum was joined by current shareholders, for a total of 117 investors. In addition to the new money, Savara raised $3.5mm via a recent bridge financing that converted to Series B shares and $1.9mm from an Emerging Technology Fund equity conversion. Proceeds will be put towards the advancement of AeroVanc through Phase IIa as the first inhaled antibiotic for Staphylococcus aureus in cystic fibrosis patients.
Deal Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies